HOUSE DOCKET, NO. 1042        FILED ON: 2/1/2021

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 2286

 

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

Carole A. Fiola

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act to reduce fraud in prescription drug abuse testing and help prevent substance abuse.

_______________

PETITION OF:

 

Name:

District/Address:

Date Added:

Carole A. Fiola

6th Bristol

2/1/2021

Alan Silvia

7th Bristol

2/1/2021

Bud L. Williams

11th Hampden

2/3/2021

Paul A. Schmid, III

8th Bristol

2/19/2021

Patrick Joseph Kearney

4th Plymouth

2/22/2021

David Allen Robertson

19th Middlesex

2/25/2021

Christopher Hendricks

11th Bristol

2/26/2021

Carlos González

10th Hampden

2/26/2021


HOUSE DOCKET, NO. 1042        FILED ON: 2/1/2021

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 2286

By Ms. Fiola of Fall River, a petition (accompanied by bill, House, No. 2286) of Carole A. Fiola and others that the Office of Medicaid be authorized to require laboratories providing toxicology testing to demonstrate functional and operational test-utilization and test-frequency control programs.  Public Health.

 

The Commonwealth of Massachusetts

 

_______________

In the One Hundred and Ninety-Second General Court
(2021-2022)

_______________

 

An Act to reduce fraud in prescription drug abuse testing and help prevent substance abuse.

 

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

SECTION ##. Chapter 118E of the general laws is hereby amended by adding at the end thereof the following new Section:

SECTION ##. To ensure appropriate and responsible use of drug testing, for laboratories providing toxicology testing, the Office of Medicaid is authorized to require that these providers demonstrate a functional and operational test-utilization and test-frequency control program that will ensure compliance with MassHealth’s utilization and frequency requirements for clinical drug testing.

Notwithstanding any general or special law to the contrary, an independent clinical laboratory, licensed under the Clinical Laboratory Improvement Amendments (CLIA) by the U.S. Centers for Medicare and Medicaid (CMS) that is located out-of-state and accredited by both the College of American Pathologists (CAP) and the New York State Clinical Laboratory Evaluation Program (CLEP), and providing and being reimbursed for managed Medicaid services in Massachusetts, shall be deemed eligible and qualified to participate as a MassHealth fee-for-service provider and eligible for payment for clinical toxicology testing purposes.  Payments made to qualified laboratories under this section will only apply when a qualified laboratory provides toxicology test results to the referring health care provider within two business days of receipt of the test specimen.